Literature DB >> 16543196

The natural history of retinal degeneration in association with cobalamin C (cbl C) disease.

Andrew M Schimel1, Marilyn Baird Mets.   

Abstract

PURPOSE: To describe the association between retinal degeneration and cobalamin C (cblC) disease and to review previously published ophthalmic data regarding cblC disease.
METHODS: Descriptive case series of three patients and compilation of all previously reported cases of cblC disease in the ophthalmic literature.
RESULTS: All three new cases presented with macular pigmentary changes and showed attenuation of electroretinographic responses. Sequential ERG (electroretinogram) testing in Case 1 demonstrated ERGs that began at the lower limits of normal and became progressively attenuated over time.
CONCLUSIONS: Cobalamin C disease results in progressive retinal degeneration with its onset in the first few months of life and progressing rapidly over the first few years of life.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16543196     DOI: 10.1080/13816810500481758

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  9 in total

1.  Retinopathy in a patient with Fanconi anemia and vitamin B12 deficiency.

Authors:  M-S Chen; K-P Chang; K-H Lin; C-L Tsai; T-C Ho
Journal:  Eye (Lond)       Date:  2011-11-04       Impact factor: 3.775

2.  A woman with bilateral maculopathy and acquired vitamin B12 deficiency.

Authors:  T Doan; J R Chao
Journal:  Eye (Lond)       Date:  2014-05-02       Impact factor: 3.775

Review 3.  Combined methylmalonic acidemia and homocystinuria, cblC type. II. Complications, pathophysiology, and outcomes.

Authors:  Nuria Carrillo-Carrasco; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

Review 4.  Cobalamin C defect: natural history, pathophysiology, and treatment.

Authors:  Diego Martinelli; Federica Deodato; Carlo Dionisi-Vici
Journal:  J Inherit Metab Dis       Date:  2010-07-15       Impact factor: 4.982

Review 5.  Ocular manifestations in patients with inborn errors of intracellular cobalamin metabolism: a systematic review.

Authors:  Karim Matmat; Rosa-Maria Guéant-Rodriguez; Abderrahim Oussalah; Arnaud Wiedemann-Fodé; Carlo Dionisi-Vici; David Coelho; Jean-Louis Guéant; Jean-Baptiste Conart
Journal:  Hum Genet       Date:  2021-10-15       Impact factor: 5.881

6.  Cobalamin C Deficiency Shows a Rapidly Progressing Maculopathy With Severe Photoreceptor and Ganglion Cell Loss.

Authors:  Lucas Bonafede; Can H Ficicioglu; Leona Serrano; Grace Han; Jessica I W Morgan; Monte D Mills; Brian J Forbes; Stefanie L Davidson; Gil Binenbaum; Paige B Kaplan; Charles W Nichols; Patrick Verloo; Bart P Leroy; Albert M Maguire; Tomas S Aleman
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

7.  Ophthalmic Manifestations and Long-Term Visual Outcomes in Patients with Cobalamin C Deficiency.

Authors:  Brian P Brooks; Amy H Thompson; Jennifer L Sloan; Irini Manoli; Nuria Carrillo-Carrasco; Wadih M Zein; Charles P Venditti
Journal:  Ophthalmology       Date:  2016-01-26       Impact factor: 12.079

8.  Brg1 coordinates multiple processes during retinogenesis and is a tumor suppressor in retinoblastoma.

Authors:  Issam Aldiri; Itsuki Ajioka; Beisi Xu; Jiakun Zhang; Xiang Chen; Claudia Benavente; David Finkelstein; Dianna Johnson; Jennifer Akiyama; Len A Pennacchio; Michael A Dyer
Journal:  Development       Date:  2015-12-01       Impact factor: 6.868

Review 9.  Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency.

Authors:  Martina Huemer; Daria Diodato; Bernd Schwahn; Manuel Schiff; Anabela Bandeira; Jean-Francois Benoist; Alberto Burlina; Roberto Cerone; Maria L Couce; Angeles Garcia-Cazorla; Giancarlo la Marca; Elisabetta Pasquini; Laura Vilarinho; James D Weisfeld-Adams; Viktor Kožich; Henk Blom; Matthias R Baumgartner; Carlo Dionisi-Vici
Journal:  J Inherit Metab Dis       Date:  2016-11-30       Impact factor: 4.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.